Skip to content

A Pharmaceutical analytical and Clinical pilot trial to evaluate efficacy of Herbal nasal spray in Allergic Rhinitis.

PHARMACEUTICAL ANALYTICAL AND CLINICAL STUDY OF HERBAL NASAL SPRAY FOR ALLERGIC RHINITIS ââ?¬â?? PILOT STUDY

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/08/044908
Enrollment
12
Registered
2022-08-25
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J309- Allergic rhinitis, unspecified

Interventions

None listed

Sponsors

Department of Rasashastra and Bhaishajya Kalpana
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Subjects willing for the trial. 2) Mild to moderate cases of Allergic rhinitis. 3) Subject in age group between 18 to 60 years.

Exclusion criteria

Exclusion criteria: 1) Subjects not willing for the trial. 2) Subjects below 18 and above 60 years. 3) Cases which require surgical intervention like nasal polyps and deviated nasal septum would be excluded. 4) Patients suffering from any chronic debilitating disease like Tuberculosis, Diabetes mellitus type 2, Asthma and other respiratory or nasal problems. 5)Pregnant ladies and lactating mothers.

Design outcomes

Primary

MeasureTime frame
Assessment of the symptoms of Allergic RhinitisTimepoint: Efficacy of treatment will be analyzed by Assessment of symptoms on Gradation like 0, 1, 2, 3. Symptoms are 1)Running nose 2)Nasal blockage 3)Sneezing 4)Headache at baseline and at the end of 7 days.

Secondary

MeasureTime frame
CBC Absolute eosinophilic Count Timepoint: Effect of treatment will be assessed on CBC, Absolute eosinophilic Count at baseline and at the end of 7 days

Countries

India

Contacts

Public ContactDr Neerja Thakur

Parul Institute of Ayurved

docvaishnavi@gmail.com9739624874

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026